Beken Bio has cut the ribbon on a new laboratory inside the New Orleans BioInnovation Center, a move the company says will speed up clinical work on its blood-based ovarian cancer test while laying the groundwork for a CLIA-certified facility. The space is expected to serve as the startup’s primary hub for clinical and operational work as it moves through regulatory review. The expansion adds another wet-lab tenant to the city’s growing BioDistrict and could bring new biotech jobs to the area.
“Establishing our lab at NOBIC is a pivotal moment for Beken Bio,” Christopher Millan, the company’s co‑founder and CEO, said in a statement to New Orleans CityBusiness. NOBIC Executive Director Kris Khalil has emphasized the center’s role in helping startups move from research to commercialization, and CityBusiness reports that the new space will support building clinical workflows and the infrastructure needed to pursue regulatory review.
How the Test Works and Why CLIA Matters
Beken Bio says its proprietary 3D REVEAL engine captures tumor‑derived extracellular vesicles from routine blood draws and uses machine learning to pinpoint cancer‑specific signatures, according to Beken Bio. The company received a National Science Foundation SBIR Phase I award to support development of a liquid‑biopsy test for ovarian cancer, a grant that helped anchor R&D and clinical partnerships in New Orleans, per the NSF award record.
CLIA certification is the federal standard for laboratories that run human diagnostic tests and sets personnel, quality control and proficiency requirements labs must meet before offering patient testing, according to the CDC. For Beken Bio, securing CLIA status at the new site would be a key step toward offering its ovarian cancer test as a clinical service.
Local Momentum and Funding
Tulane Ventures has invested $125,000 in Beken Bio to support clinical studies, hiring and equipment as the company scales, according to New Orleans CityBusiness. The startup has also raised seed support from Boot64, the New Orleans BioFund and 1834 Ventures, while national impact investors have joined in to help finance the move.
The Community Development Venture Capital Alliance says it co‑invested alongside the New Orleans BioFund to help pay for the CLIA lab build‑out, signaling that local and impact investors are lining up behind the BioDistrict strategy (Community Development Venture Capital Alliance).
What’s Next for Beken Bio
In the coming months, Beken Bio plans to outfit its NOBIC lab for clinical workflows, pursue CLIA certification and run pilot studies with hospital partners in the region, the incubator says. The company’s SBIR program outlines plans to evaluate extracellular vesicle‑based markers with gynecologic oncologists at LCMC Health and Ochsner Medical Center as part of early validation, according to the New Orleans BioInnovation Center.
If the lab clears CLIA validation and meets clinical benchmarks, it could become the foundation for a laboratory‑based ovarian cancer test offered locally as Beken Bio advances commercialization.
